Haloperidol IV is the next-line antiemetic for cannabinoid hyperemesis syndrome when ondansetron and promethazine have failed.
For intractable vomiting in CHS refractory to standard antiemetics, use haloperidol 0.05-0.1 mg/kg IV (typically 5 mg for most adults) as your next agent. This represents the strongest evidence-based option when first-line therapies fail.
Evidence-Based Rationale
The most compelling data comes from a randomized controlled trial directly comparing haloperidol to ondansetron in CHS patients 1. Haloperidol demonstrated superiority with a 2.3 cm greater reduction in combined pain/nausea scores on visual analog scale (95% CI 0.6-4.0 cm, P=0.01), reduced need for rescue antiemetics (31% vs 59%), and shorter ED stays (3.1 vs 5.6 hours) 1. This trial used doses of 0.05-0.1 mg/kg IV, both of which were effective.
Multiple systematic reviews and treatment guidelines now recommend haloperidol as a preferred agent for CHS 2, 3, 4, 5. The San Diego Emergency Medicine consensus guideline specifically positions antipsychotics including haloperidol as having "complete symptom relief in limited case studies" while noting conventional antiemetics have "limited effectiveness" 4.
Practical Dosing Algorithm
Start with haloperidol 5 mg IV (or 0.05-0.1 mg/kg) given over 2-5 minutes:
- For patients <70 kg: use 0.05 mg/kg (approximately 2.5-4 mg)
- For patients ≥70 kg: use 5 mg
- Can repeat once after 30-60 minutes if inadequate response
- Maximum 10 mg in first 2 hours
Monitor for acute dystonia (occurred in 2/13 patients in the higher-dose group in the trial) 1. Have diphenhydramine 25-50 mg IV available for immediate treatment of dystonic reactions.
Alternative Second-Line Options
If haloperidol is contraindicated or unavailable:
Olanzapine 5-10 mg PO/SL is supported by NCCN guidelines for breakthrough chemotherapy-induced vomiting (category 1 evidence) 6 and multiple CHS treatment algorithms 3, 4, 5. While studied primarily in chemotherapy contexts, the mechanism and efficacy translate to CHS.
Droperidol 0.625-1.25 mg IV is mentioned in recent CHS literature as an effective dopamine antagonist 3, though less studied than haloperidol.
What NOT to Use
Avoid repeating the same class of antiemetics that already failed:
- Additional 5-HT3 antagonists (granisetron, dolasetron) won't help if ondansetron failed
- Metoclopramide 10-20 mg IV is listed in breakthrough guidelines 6 but has limited efficacy in CHS specifically 4, 5
- Opioids should be avoided - they worsen nausea and carry addiction risk without addressing CHS pathophysiology 7, 3, 4
Adjunctive Measures
Topical capsaicin 0.1% cream applied to abdomen can provide additional relief through TRPV1 receptor activation 7, 2, 4. The San Diego consensus guideline recommends this as "reasonable first-line treatment" 4.
Benzodiazepines (lorazepam 0.5-2 mg IV) may help with anxiety and anticipatory nausea 6, 5 but should not be primary therapy.
Critical Pitfall
The most common error is continuing to escalate conventional antiemetics (ondansetron, promethazine, metoclopramide) when they've already failed. CHS responds poorly to standard antiemetics because the pathophysiology involves cannabinoid receptor dysregulation, not the typical serotonergic or dopaminergic pathways these drugs target 7, 4. Switching to a dopamine D2 antagonist like haloperidol addresses a different mechanism.
Long-Term Management
While managing the acute episode, counsel the patient that cannabis cessation is the only definitive cure 7, 4. Consider initiating amitriptyline 25 mg at bedtime (titrate to 75-100 mg) for prophylaxis if the patient is willing to attempt cessation 7.